IHC & ISH
NeoTYPE™ Tumor Profiles
NeoLAB EGFR T790M – Liquid Biopsy testing is now being offered at NeoGenomics Laboratories
to detect the T790M acquired resistance mutation with very high sensitivity (0.1%) using cell-free
circulating tumor DNA. This new assay provides a powerful alternative for situations involving limited
access to tissue samples.
For NSCLC patients that have developed an
acquired resistance to prior TKI treatment and
are suspected to have an EGFR T790M acquired
resistance mutation. Helpful in situations where
limited or no tissue is available for testing and
for identifying patients that may respond to third
generation EGFR TKIs.